Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  D'allard, Diane ^a,b,c,d,e   Gay, Julie ^a,b,c,d   Descarpentries, Clotilde ^a,b,c,d   Frisan, Emilie ^a,b,c,d   Adam, Kevin ^a,b,c,d,e   Verdier, Frederique ^a,b,c,d,e   Floquet, Célia ^a,b,c,d,e   Dubreuil, Patrice ^f   Lacombe, Catherine ^a,b,c,d,e,g   Fontenay, Michaela ^a,b,c,d,e,g   Mayeux, Patrick ^a,b,c,d,e   Kosmider, Olivier ^a,b,c,d,e,g  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Cartes d'Identité des Tumeurs Program   (France)

^e Laboratoire d'Excellence GR Ex   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CBL PROTEIN; IMATINIB; LIGAND; MASITINIB; METHYL BETA CYCLODEXTRIN; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR; TYROSINE; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; CELL LINE; CELL STRAIN EPO; CELL STRAIN UT 7; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTERNALIZATION; LYSOSOME; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; ANTAGONISTS AND INHIBITORS; BINDING SITE; CYTOLOGY; DRUG EFFECTS; ERYTHROBLAST; METABOLISM; PROTEIN TRANSPORT;

ADENOSINE TRIPHOSPHATE; BENZAMIDES; BINDING SITES; CELL LINE; DOWN-REGULATION; ERYTHROBLASTS; HUMANS; LIGANDS; LYSOSOMES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PROTEIN-TYROSINE KINASES; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; THIAZOLES;

EID: 84876586327     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060961     Document Type: Article

References (38)

1. Muta K, Krantz SB, Bondurant MC, Dai CH, (1995) Stem cell factor retards differentiation of normal human erythroid progenitor cells while stimulating proliferation. Blood 86: 572-80.
2. Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, et al. (2007) Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 130: 323-34.
3. Orinska Z, Föger N, Huber M, Marschall J, Mirghomizadeh F, et al. (2010) I787 provides signals for c-Kit receptor internalization and functionality that control mast cell survival and development.Blood. 116: 2665-75.
4. Wilde A, Beattie EC, Lem L, Riethof DA, Liu SH, et al. (1999) EGF receptor signaling stimulates SRC kinase phosphorylation of clathrin, influencing clathrin redistribution and EGF uptake. Cell 96: 677-87.
5. He YY, Huang JL, Gentry JB, Chignell CF, (2003) Epidermal growth factor receptor down-regulation induced by UVA in human keratinocytes does not require the receptor kinase activity.J Biol Chem. 278: 42457-65.
6. Wang Q, Villeneuve G, Wang Z, (2005) Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation EMBO Rep. 6: 942-8.
7. Yee NS, Hsiau CW, Serve H, Vosseller K, Besmer P, (1994) Mechanism of down-regulation of c-kit receptor. Roles of receptor tyrosine kinase, phosphatidylinositol 3'-kinase, and protein kinase C. J Biol Chem 269: 31991-8.
8. Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, et al. (1995) Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85: 790-8.
9. Masson K, Heiss E, Band H, Rönnstrand L, (2006) Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation.Biochem J. 399: 59-67.
10. Bandi SR, Brandts C, Rensinghoff M, Grundler R, Tickenbrock L, et al. (2009) E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. Blood 114: 4197-208.
11. Lennartsson J, Rönnstrand L, (2012) Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications. Physiol Rev 92: 1619-49.
12. Heinrich MC, Blanke CD, Druker BJ, Corless CL, (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20: 1692-703.
13. Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, et al. (2005) Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106: 721-4.
14. Kosmider O, Denis N, Lacout C, Vainchenker W, Dubreuil P, et al. (2005) Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. Cancer Cell 8: 467-78.
15. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, et al. (2009) PLoS One. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. 4: e7258.
16. Zermati Y, De Sepulveda P, Féger F, Létard S, Kersual J, et al. (2003) Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22: 660-4.
17. Frisan E, Vandekerckhove J, de Thonel A, Pierre-Eugène C, Sternberg A, et al. (2012) Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. Blood 119: 1532-42.
18. Cox J, Mann M, (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26: 1367-72.
19. Walrafen P, Verdier F, Kadri Z, Chrétien S, Lacombe C, et al. (2005) Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 105: 600-8.
20. Verdier F, Walrafen P, Hubert N, Chretien S, Gisselbrecht S, et al. (2000) Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. J Biol Chem 275: 18375-81.
21. Rodal SK, Skretting G, Garred O, Vilhardt F, van Deurs B, et al. (1999) Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol Biol Cell 10: 961-974.
22. Subtil A, Gaidarov I, Kobylarz K, Lampson MA, Keen JH, et al. (1999) Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc Natl Acad Sci U S A 96: 6775-6780.
23. Zeng S, Xu Z, Lipkowitz S, Longley JB, (2005) Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl). Blood 105: 226-32.
24. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, et al. (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1: 376-86.
25. Tamborini E, Pricl S, Negri T, Lagonigro MS, Miselli F, et al. (2006) Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene 25: 6140-6.
26. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, et al. (2004) A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127: 294-9.
27. Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, et al. (2007) Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 14: 3204-15.
28. Waterman H, Levkowitz G, Alroy I, Yarden Y, (1999) The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J Biol Chem 274: 22151-4.
29. Sun J, Pedersen M, Bengtsson S, Rönnstrand L, (2007) Grb2 mediates negative regulation of stem cell factor receptor/c-Kit signaling by recruitment of Cbl. Exp Cell Res. 313: 3935-42.
30. Padron D, Sato M, Shay JW, Gazdar AF, Minna JD, et al. (2007) Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized. Cancer Res 67: 7695-702.
31. Broudy VC, Lin NL, Liles WC, Corey SJ, O'Laughlin B, et al. (1999) Signaling via Src family kinases is required for normal internalization of the receptor c-Kit. Blood 94: 1979-86.
32. Bosbach B, Deshpande S, Rossi F, Shieh JH, Sommer G, et al. (2012) Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci U S A 109: 2276-83.
33. Heinrich MC, Marino-Enriquez A, Presnell A, Donsky RS, Griffith DJ, et al. (2012) Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. Mol Cancer Ther 11: 1770-80.
34. Zhang HL, Zhu Y, Qin XJ, Wang CF, Yao XD, et al. (2012) c-KIT: Potential Predictive Factor for the Efficacy of Sorafenib in Metastatic Renal Cell Carcinoma With Sarcomatoid Feature. Clin Genitourin Cancer 12: 00174-7.
35. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, et al. (2004) Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279: 31655-63.
36. Komatsu N, Nakauchi H, Miwa A, Ishihara T, Eguchi M, et al. (1991) Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival. Cancer Res 51: 341-8.
37. Yang Y, Létard S, Borge L, Chaix A, Hanssens K, et al. (2010) Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood 116: 1114-23.
38. Collins MK, Downward J, Miyajima A, Maruyama K, Arai K, et al. (1988) Transfer of functional EGF receptors to an IL3-dependent cell line. J Cell Physiol 137: 293-8.